Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial

por Johansen, Nicklas Järvelä, Dejgaard, Thomas Fremming, Lund, Asger, Vilsbøll, Tina, Andersen, Henrik Ullits, Knop, Filip Krag
Publicado 2018

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomis...

por Dejgaard, Thomas Fremming, Knop, Filip Krag, Tarnow, Lise, Frandsen, Christian Seerup, Hansen, Tanja Stenbæk, Almdal, Thomas, Holst, Jens Juul, Madsbad, Sten, Andersen, Henrik Ullits
Publicado 2015

Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes

por Hansen, Christian Stevns, Frandsen, Christian Seerup, Fleischer, Jesper, Vistisen, Dorte, Holst, Jens Juul, Tarnow, Lise, Knop, Filip Krag, Madsbad, Sten, Andersen, Henrik Ullits, Dejgaard, Thomas Fremming
Publicado 2019